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Abstract Previous studies have shown that certain tumor cell
lines which naturally express high levels of the epidermal growth
factor receptor (EGFR) undergo apoptosis when exposed to
epidermal growth factor. Whether this phenomenon is a direct
result of receptor overexpression or some other genetic alteration
renders these cells sensitive to apoptosis is yet to be established.
We show that experimentally increasing the level of EGFR
expression predictably leads to apoptosis in a variety of cell types
which requires an active tyrosine kinase but not EGFR
autophosphorylation sites. Expression of a dominant negative
Ras mutant in EGFR overexpressing cells results in a significant
potentiation of EGFR induced apoptosis suggesting that Ras
activation is a key survival signal generated by the EGFR. We
propose that potentiation of EGFR induced apoptosis by
dominant negative Ras results, at least in part, by a block of
Akt activation. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
The epidermal growth factor receptor (EGFR) is commonly
overexpressed in cancer [1] and increased EGFR expression
correlates with malignant progression. Paradoxically, how-
ever, ligand stimulation of cells which overexpress the
EGFR has previously been shown to result in apoptosis
[2,3]. Previous studies, however, have not addressed whether
the high levels of receptor expression per se lead to ligand
induced apoptosis or whether some other genetic alteration
has rendered these cells abnormally sensitive to the e¡ects of
epidermal growth factor (EGF). It is also unknown if EGFR
induced apoptosis is an unusual feature of certain tumor cell
lines or whether it is a general consequence of EGFR over-
expression.
Activation of the EGFR tyrosine kinase results in the gen-
eration of a number of intracellular signals which culminate in
cell proliferation [4,5]. One key signal generated by the acti-
vated EGFR is the activation of p21 Ras [6], which in turn
controls the activity of a number of downstream e¡ectors
exerting complex e¡ects ranging from proliferation to di¡er-
entiation and cell death [7]. Earlier studies had identi¢ed a key
role for Ras in mitogenic signaling [8]. However, more recent
studies suggest a more complex role of p21 Ras. For example,
introduction of p21 Ras into primary cells results in growth
arrest [9]. Ras signaling also plays a regulatory role in apo-
ptosis, which may be pro- or antiapoptotic [7].
A kinase inactive EGFR mutant is unable to signal mito-
genesis, but retains the ability to generate certain EGF in-
duced signals such as mitogen activated protein kinase activa-
tion [10]. Interestingly, a mutant EGFR which lacks all ¢ve
autophosphorylation sites retains the ability to signal mito-
genesis [11]. This mutant receptor can activate p21 Ras and
tyrosine phosphorylate Shc in response to EGF [12]. In this
study we demonstrate that apoptosis is a direct and predict-
able outcome of EGFR overexpression in a variety of cell
lines and explore the role of Ras signaling in EGFR induced
apoptosis.
2. Materials and methods
2.1. Materials
2.1.1. Cell lines. 293 EBNA cells were obtained from Invitrogen
(Carlsbad, CA, USA). R1hER cells were obtained from Dr. Michael
Weber (Charlottesville, VA, USA). U-87 MG and C6 glioma cells
were obtained from ATCC.
2.1.2. DNA. A human EGFR construct cloned into pCDNA 3.1
[13] was used for transient transfection experiments. A kinase inactive
mutant EGFR, CMV Neo-HER M721, was obtained from Dr. Axel
Ullrich (Martinsried, Germany). A truncated EGFR mutant lacking
all ¢ve major autophosphorylation sites was generated by PCR am-
pli¢cation of a 300 bp internal fragment of the EGFR gene introduc-
ing a stop codon before the ¢rst tyrosine residue (Y992). This frag-
ment was cloned in pCDNA 3.1+ with the region of the EGFR gene
upstream of the ampli¢ed sequence. A pSV-L-galactosidase control
vector was obtained from Promega (Madison, WI, USA). pMMTV-
rasH(Asn-17) and pMMTV v-Ras expression plasmids were obtained
from Dr. Geo¡rey Cooper (Boston, MA, USA), described in [14].
2.1.3. Antibodies. EGFR and phospho-Akt antibodies (05-104
and 06-801) were purchased from Upstate Biotechnology (Lake Plac-
id, NY, USA). A pan Ras antibody (Clone Ras 10, OP40) was pur-
chased from Oncogene Research Products (Cambridge, MA, USA).
Anti-phospho ERK antibodies (Cat. No. V6671) were obtained from
Promega (Madison, WI, USA). ERK2 and Akt antibodies (sc-154 and
sc-8312) were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
2.2. Transfection
A standard calcium phosphate protocol was used for all transfec-
tions described in this study [15]. For creation of stable cell lines,
R1hER cells were transfected using the calcium phosphate method
and mass populations of G418 resistant cells were pooled and tested
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for expression of Ras by Western blotting following exposure to dexa-
methasone.
2.3. Immunoprecipitation and Western blotting
Immunoprecipitation and Western blotting were performed as pre-
viously described [13].
2.4. Assays for cell death
2.4.1. Morphological analysis. Cells were transfected with an ex-
pression vector for L-galactosidase (L-Gal) along with the EGFR or
control vector, or with empty vector or EGFR without L-Gal, for the
time periods indicated in the ¢gure legends followed by X-Gal stain-
ing for cells transfected with L-Gal according to standard protocols
[15]. Blue cells were de¢ned as dead or alive based on the morpho-
logical criteria described in Section 3.
2.4.2. DNA laddering. DNA was extracted from cells using an
Easy-DNA kit from Invitrogen (Carlsbad, CA, USA) according to
the manufacturer’s protocol and analyzed on a 2% agarose gel stained
with ethidium bromide.
2.4.3. Cell death detection ELISA. A cell death detection ELISA
kit (Cat. No. 1774425) was obtained from Boehringer Mannheim USA
and used according to the manufacturer’s protocol. This is a photo-
metric enzyme immunoassay for the quantitative detection of cytoplas-
mic histone associated DNA fragments after induced cell death.
3. Results
3.1. Apoptosis is a predictable outcome of EGFR
overexpression in various cell lines
R1hER cells are Rat-1 ¢broblasts transfected with the hu-
man EGFR expressing about 7.5U105 EGF receptors, which
is approximately a sevenfold increase over the parental Rat-1
cells [16]. When exposed to EGF, R1hER cells undergo apo-
ptosis. In contrast, addition of EGF to Rat-1 cells results in a
modest mitogenic e¡ect without evidence of apoptosis. Addi-
tion of EGF to R1hER cells results in apoptosis detectable
within 24 h with most cells dying within 48 h. While unstim-
ulated R1hER cells grow to con£uence, cells exposed to EGF
show morphologic features of apoptosis including cell shrink-
age, membrane blebbing, and nuclear condensation (Fig.
1A,B). DNA fragmentation, a cardinal feature of apoptosis,
was evident in EGF treated R1hER cells but not in untrans-
fected Rat-1 ¢broblasts treated with EGF (Fig. 1D), further
demonstrating that the EGF mediated cell death is apoptotic.
In Fig. 1 R1hER cells were treated with EGF at a concen-
tration of 100 ng/ml. Apoptosis can also be detected when
these cells are treated with lower concentrations of EGF
(Fig. 5A).
The transient overexpression of the EGFR also results in
apoptosis in various cell lines. Using a L-Gal cotransfection
assay which has been widely used to assess apoptosis in tran-
siently transfected cells [17], we transiently overexpressed the
EGFR along with a L-Gal gene in 293 EBNA cells. This
resulted in the death of more than 90% of transfected 293
EBNA cells within 24 h (Fig. 2B), with cells displaying mor-
phological alterations of adherent cells undergoing apoptosis,
becoming rounded and condensed, and detaching from the
dish. Cell death was not observed when the vector alone
was cotransfected with L-Gal (Fig. 2A). Fig. 2C,D shows
293 cells transfected with vector alone or EGFR alone. Since
Fig. 1. EGF induces apoptosis in R1hER cells. EGF was added to cells in the presence of 10% fetal bovine serum for 48 h at a concentration
of 100 ng/ml and cells were photographed under phase contrast microscopy. A: Unstimulated R1hER (Rat-1 cells overexpressing the EGFR)
cells. B: R1hER cells stimulated with EGF. C: R1hER cells preincubated with tyrphostin AG 1478 (100 nM) for 2 h before addition of EGF
for 48 h. No apoptosis could be detected in the parental Rat-1 cells in response to EGF (not shown). D: DNA fragmentation that results
from EGF stimulation in R1hER cells but not in untransfected Rat-1 ¢broblasts. Lane 1 shows R1hER cells treated with EGF, with the ap-
pearance of DNA laddering seen in apoptosis. Lane 2 shows unstimulated R1hER cells. Lane 3 shows Rat-1 ¢broblasts treated with EGF.
Lane 4 shows Lambda/HindIII molecular weight markers.
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our transfection e⁄ciency in this cell line is high (about 30%),
apoptosis can be detected morphologically in these cells even
in the absence of L-Gal as a marker (Fig. 2D). Trypan blue
staining of cells transfected with the EGFR showed that
about 30% of cells failed to exclude the dye whereas 95% of
cells transfected with the vector alone were viable (not
shown). Expression of the EGFR was con¢rmed by immuno-
blotting in parallel experiments (not shown). We also observe
DNA fragmentation in cells transfected with the EGFR but
not in vector transfected cells, con¢rming that the cell death is
apoptotic (Fig. 2E).
EGFR induced apoptosis in 293 EBNA cells is ligand in-
dependent due to maximal tyrosine phosphorylation of the
EGFR upon ectopic expression in these cells. Addition of
EGF does not result in a further increase in tyrosine phos-
phorylation of the receptor in these cells [18]. Ligand inde-
pendent signaling by ectopically expressed EGFR has also
been noted in 293T cells [19]. Overexpression of the EGFR
also leads to ligand dependent apoptosis in U-87 MG cells
and in C6 glioma cells (not shown).
Thus EGFR overexpression can lead to ligand dependent
apoptosis in cell types as diverse as epithelial (MDA-MB-468,
A431, and 293), mesenchymal (Rat-1 ¢broblasts), and glial
(U-87 MG and C6) cells.
3.2. EGFR mediated apoptosis requires an active tyrosine
kinase but not EGFR autophosphorylation sites
To understand the molecular mechanism by which the over-
Fig. 2. EGFR overexpression induces a ligand independent apoptosis in 293 EBNA cells. Cells were plated overnight in Dulbecco’s modi¢ed
Eagle’s medium/10% fetal bovine serum in 6 well dishes. Transfections were performed the next day using the calcium phosphate method.
A: Cells were transfected with L-Gal (1 Wg) plus an empty vector (4 Wg) or EGFR. B: Cells were stained with X-Gal 24 h after transfection.
C,D: Cells were transfected with an empty vector or EGFR (20 Wg) and photographed after 48 h. E: DNA fragmentation in 293 cells trans-
fected with the EGFR (lane 1), but not with the empty vector (lane 2). Lane 3 shows molecular weight markers.
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expressed EGFR induces apoptosis we examined the ability of
EGFR mutants to induce apoptosis. A mutant EGFR lacking
intrinsic tyrosine kinase activity does not induce apoptosis in
transiently transfected 293 cells (Fig. 3A,C). Pretreatment of
R1hER cells with tyrphostin AG 1478, a speci¢c EGFR ki-
nase inhibitor, also blocks EGF mediated apoptosis in
R1hER cells (Fig. 1C). However, the EGFR with intact tyro-
sine kinase activity but lacking its ¢ve autophosphorylation
sites, hence lacking the putative binding sites for SH2 domain
proteins, potently induces apoptosis in these cells (Fig. 3B,D).
3.3. A dominant negative Ras mutant potentiates apoptosis
induced by the EGFR: a possible role of Akt
Since the truncated EGFR lacking all ¢ve major autophos-
phorylation sites is competent to generate the apoptotic signal
and previous studies have shown that this mutant receptor
retains the ability to activate Ras in response to mitogenic
signals, we tested whether a key apoptotic signal was trans-
mitted through p21 Ras by creating created stable R1hER cell
lines expressing a dominant negative Ras (N17) mutant under
the control of a dexamethasone inducible promoter. To con-
¢rm that the transfected dominant negative Ras construct was
functional we veri¢ed that EGF induced ERK activation is
signi¢cantly attenuated in cells transfected with dominant
negative Ras (Fig. 4B) compared to empty vector. We ¢nd
that EGF induced apoptosis is dramatically increased in
cells transfected with a dominant negative Ras (Fig. 5B).
The results of a quantitative photometric ELISA for DNA
fragmentation (Fig. 5C) also demonstrate an increase in
EGF mediated apoptosis in cells expressing dominant nega-
tive Ras.
Previous studies have shown that activation of phosphati-
dylinositol 3-kinase (PI 3-kinase) is Ras dependent [20]. Acti-
vation of PI 3-kinase results in activation of protein kinase
B/Akt which is known to be a key antiapoptotic signal [21].
We ¢nd that Akt activation is blocked in R1hER cells ex-
pressing a dominant negative Ras mutant but not in R1hER
cells expressing the empty vector (Fig. 5D). This suggests that
the e¡ect of dominant negative Ras in potentiating EGFR
mediated apoptosis is at least in part due to a block of Akt
activation. The EGFR is functional in R1hER cells expressing
dominant negative Ras since EGF induced activation of
STAT1 is not attenuated in these cells compared to R1hER
cells expressing empty vector (not shown).
4. Discussion
While previous studies have shown that EGF induces apo-
ptosis in certain tumor cells lines which naturally overexpress
the EGFR it has not been rigorously established that this
apoptosis is a direct result of EGFR overexpression. In this
study we show that transient or stable overexpression of the
EGFR predictably leads to ligand dependent apoptosis in a
variety of cell lines suggesting that apoptosis may be a general
outcome of EGFR overexpression. A previous study has also
reported that stimulation of tumor cells overexpressing the
Fig. 3. EGFR mediated apoptosis requires an active tyrosine kinase but not EGFR autophosphorylation sites. A: Cells were transfected with
L-Gal (1 Wg) plus a kinase inactive EGFR mutant (4 Wg). B: Cells were transfected with L-Gal plus a truncated EGFR mutant (4 Wg) which
lacks all ¢ve major autophosphorylation sites. Cells were stained with X-Gal 24 h after transfection. C,D: Cells were transfected with vector
alone or EGFR respectively (20 Wg) and photographed after 48 h.
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ErbB2 receptor with Heregulin induces apoptosis [22] suggest-
ing that apoptosis may be an outcome of high levels of ex-
pression of other receptor tyrosine kinases as well.
The exact level of EGFR expression where a mitogenic
stimulus changes into a death stimulus probably varies de-
pending on the cell type. A431 cells and MDA-MB-468 cells
express about 2U106 receptors [23] while R1hER cells express
about 7.5U105 receptors, about a sevenfold increase over un-
transfected Rat-1 ¢broblasts.
EGFR mediated apoptosis, like mitogenic signaling, re-
quires an active kinase but not EGFR autophosphorylation
sites, indicating that the truncated receptor can generate the
apoptotic signal. Since in previous studies the truncated re-
ceptor has been shown to activate p21 Ras, a critical compo-
nent of mitogenic signaling, we studied the e¡ect of inhibiting
Ras signaling on EGF mediated apoptosis. We ¢nd that in-
hibiting Ras signaling results in a signi¢cant potentiation of
EGFR induced apoptosis.
p21 Ras has recently been discovered to be a key modulator
of apoptosis induced by other stimuli as well. For example,
Ras activation may be required for apoptosis induced by the
tumor necrosis factor and by Fas [24,25]. Activated Ras may
render cells sensitive to apoptosis induced by downregulation
of protein kinase C [26]. Activation of p21 Ras also results in
the activation of the antiapoptotic PI 3-kinase/Akt pathway.
We ¢nd that Akt activation is signi¢cantly impaired in cells
expressing dominant negative Ras suggesting that the poten-
tiation of EGFR induced apoptosis in these cells may result
from impaired Akt activation. Attenuation of ERK activity
may also contribute to the increased apoptosis seen in cells
expressing dominant negative Ras, since ERK activity has
previously been shown to be antiapoptotic [27].
While the mechanism of EGFR induced apoptosis remains
unknown a recent study has proposed that EGFR mediated
apoptosis requires detachment of cells from the substratum
[28]. This was based in part on ¢nding evidence of caspase
activation only in detached MDA-MB-468 cells following
EGF treatment. Our study does not support the hypothesis
that cell detachment is required for EGFR mediated apopto-
sis. All our experiments were performed in adherent cells and
we consistently found both morphological and biochemical
evidence of apoptosis in adherent cells treated with EGF.
Fig. 4. Expression of a dominant negative Ras mutant potentiates EGF induced apoptosis. A: Cells transfected with dominant negative Ras
(lanes 1 and 2) in which an increase in Ras levels can be detected upon exposure to dexamethasone (1 WM) for 16 h while such an increase is
not detected in the vector transfected R1hER cells (lanes 3 and 4). B: Cells expressing dominant negative Ras were tested for their ability to
activate ERK2 (using a phosphospeci¢c antibody) in response to EGF following exposure to dexamethasone. Cells expressing dominant nega-
tive Ras show a smaller increase in ERK activation in response to growth factor (lanes 3 and 4) compared to vector transfected cells (lanes 1
and 2). The blot was stripped and reprobed with ERK2 antibodies to determine protein loading (lower panel).
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This suggests that caspase activation may be a late feature of
EGFR induced apoptosis.
The EGFR is overexpressed in many types of cancers and
correlates with malignant progression. In this study we dem-
onstrate that apoptosis is a predictable outcome of EGFR
overexpression in a variety of cell types. To reconcile these
apparently con£icting observations, we propose the following
hypothesis. During the clonal evolution of a tumor low levels
of receptor activation may promote mitogenesis and confer a
growth advantage to cells. Since the levels of circulating li-
gand in vivo are low, tumors may select for cells overexpress-
ing receptors to sustain their growth. Beyond a certain thresh-
old of receptor expression, however, cells may undergo
apoptosis as a result of high levels of receptor activation
when exposed to exogenous ligand, especially at pharmaco-
logic doses. Whether there are subsets of human tumors over-
expressing the wild-type EGFR that undergo apoptosis in
response to EGF in vivo remains to be determined, and is,
we believe, a question that deserves further study.
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